Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vorapaxar - Aralez/Merck & Co

Drug Profile

Vorapaxar - Aralez/Merck & Co

Alternative Names: MK-5348; SCH-530348; TRA; TRA-SCH-530348; Vorapaxar sulfate; Zontivity

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Aralez Pharmaceuticals Inc.; Duke Clinical Research Institute; Kirby Institute for infection and immunity in society; Merck & Co
  • Class 3-ring heterocyclic compounds; Antithrombotics; Carbamates; Cardiovascular therapies; Lactones; Pyridines
  • Mechanism of Action PAR 1 receptor antagonists; Thrombin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial thrombosis
  • Phase I/II Blood coagulation disorders; Inflammation
  • No development reported Cerebral infarction

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Apr 2018 Vorapaxar is not yet launched for Arterial thrombosis (Prevention) in Canada
  • 14 Mar 2018 Aralez Pharmaceuticals has patents issued and pending for vorapaxar in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top